SciBase's Strategic Expansion in the U.S. Melanoma Diagnostic Market: Accelerating Growth Through Innovation and Partnerships

The global dermatology diagnostics market is on the brink of a revolution, driven by rising skin cancer incidence and the urgent need for early detection tools. With over 190,000 new melanoma cases projected in the U.S. this year alone, the demand for non-invasive, AI-driven diagnostic solutions has never been greater. Enter SciBase Holding AB, a Stockholm-based medtech leader whose Nevisense platform is poised to dominate this space. Combining advanced electrical impedance spectroscopy (EIS) with artificial intelligence, SciBase is not just keeping pace with the market—it's redefining it.

Palm Beach Dermatology Group: A Catalyst for Market Penetration

In July 2025, SciBase secured a landmark partnership with Palm Beach Dermatology Group, a Florida-based leader in skin care with over 30 years of clinical expertise. The group purchased six Nevisense devices and electrodes in an initial order valued at approximately KUSD 50, marking a critical step in expanding the platform's footprint in one of the U.S.'s highest melanoma-risk regions.

The deal's significance extends beyond immediate revenue. Nevisense's AI-driven diagnostics enable non-invasive early melanoma detection, which has a nearly 100% cure rate when caught early. Palm Beach Dermatology Group's adoption sets a precedent for other U.S. clinics, particularly in sunbelt states where skin cancer rates are soaring. Crucially, the recurring revenue model—where electrodes are replaced regularly—ensures a steady income stream for SciBase, a key metric for long-term investment stability.

Scaling U.S. Operations: The Leda & Dan Duo

SciBase's growth hinges on two pivotal hires: Leda Beaty, Head of U.S. Commercial Operations, and Dan Walker, VP of U.S. Commercial Operations. Together, they are orchestrating a strategic push into the U.S. market, leveraging decades of experience in dermatology, reimbursement, and product launches.

• Leda Beaty: With 27 years in pharmaceuticals and medtech sales (including roles at Aventis and Amgen), Leda is spearheading strategic partnerships with dermatology centers and clinicians. Her focus on market access and team-building in key states like Texas and California is accelerating Nevisense's adoption.
• Dan Walker: A 24-year veteran of U.S. healthcare reimbursement systems, Dan is navigating the complex landscape of Medicare/Medicaid coverage. His work with MACs (Medicare Administrative Contractors) is critical for ensuring Nevisense is reimbursed as a standard diagnostic tool, reducing financial barriers for clinics.

Their combined efforts have already yielded results: SciBase's U.S. salesforce has expanded, and the company is actively showcasing Nevisense at major conferences like the 2024 Winter Clinical Dermatology Conference, where physicians can witness its efficacy firsthand.

Validated Technology and Expanding Applications

Nevisense's clinical credibility is underscored by over 20 years of research at the Karolinska Institute and recent FDA approvals. In June 2025, SciBase launched a Self-Pay Program to bypass insurance delays, making Nevisense accessible to cash-paying patients—a shrewd move in a market where 1 in 5 Americans lacks traditional coverage.

Moreover, Nevisense's utility is expanding beyond melanoma. A 2025 collaboration with Castle Biosciences aims to develop a predictive test for atopic dermatitis flares, leveraging EIS data. This partnership—funded by a SEK 19M equity investment from Castle—not only diversifies SciBase's revenue streams but also positions its technology as a platform for broader dermatological insights.

The Investment Case: Strong Fundamentals, Growing Momentum

SciBase's strategy is a masterclass in value creation through differentiation:
1. Clinical Validation: Nevisense's FDA and MDR approvals, paired with peer-reviewed studies, reduce regulatory risk.
2. Recurring Revenue: The electrode replacement model provides predictable cash flows, a rare commodity in medtech.
3. Market Expansion: Florida's Palm Beach partnership is a template for future U.S. rollouts, while the Castle deal opens doors to chronic skin conditions like psoriasis.

Investors should watch for two catalysts:
- Reimbursement Wins: If Medicare/Medicaid coverage expands, Nevisense's adoption could surge.
- Partnership Announcements: New collaborations with academic institutions or clinics will validate SciBase's market pull.

Risks and Considerations

• Regulatory Hurdles: AI-driven diagnostics face evolving scrutiny, though SciBase's FDA track record mitigates this risk.
• Market Saturation: Competitors like Skinmap are also pushing AI tools, but Nevisense's proven efficacy and Karolinska pedigree offer a defensible edge.

Conclusion: A High-Growth Opportunity in a Critical Market

SciBase is uniquely positioned to capitalize on the $1.8 billion U.S. dermatology diagnostics market, which is projected to grow at a 6.5% CAGR through 2030. With Palm Beach Dermatology's endorsement, a world-class leadership team, and a technology validated in both academia and clinics, SciBase is not just a player—it's a leader.

For investors seeking exposure to early detection innovation, SciBase offers a compelling mix of clinical credibility, scalable revenue, and strategic execution. As dermatology shifts toward AI-driven precision, this Stockholm-based pioneer is writing the future of skin health—one diagnostic scan at a time.

Consider SciBase for portfolios focused on medtech innovation, but monitor reimbursement approvals and partnership progress for near-term upside.